Kidney transplant rejection trial pulled before it began
NCT ID NCT02113891
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study was designed to test whether the drug eculizumab could treat early, symptom-free antibody-mediated rejection in kidney transplant recipients. The goal was to prevent long-term damage and chronic rejection. However, the trial was withdrawn before enrolling any participants, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Eculizumab (Soliris)
- What this could lead to
- If this approach had worked, it could have pointed toward a way to prevent chronic rejection and extend kidney transplant survival.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no results are available. The approach remains unproven and carries risks like increased infections due to complement blockade.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.